Linkedin Youtube Instagram Facebook
Linkedin Youtube Instagram Twitter Facebook

Mindset Pharma is a leader in developing next-generation psychedelic medicines to treat neurological and psychiatric disorders.

Download the presentation
Download
ABOUT US

Company Overview

Mindset Pharma is a Toronto-based drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders.

Play Video

Pipeline

Mindset has developed 4 families of novel, next-generation psychedelics with differentiated characteristics and improved safety profiles. Read More

Click to enlarge

Family

Family 1 / MSP-1014: Psilocybin-like conjugate.

Family 2: High-potency, short-acting, psilocybin-like.

Family 3: Low-potency, long-duration for micro-dosing

Family 4: DMT/ 5-MeO-DMT-inspired compounds

Lead Identification

Lead Optimization

IND-Enabling

Clinical
Phase 1

Recent News

Apr 26, 2023
Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds
Read more
Read more
Apr 03, 2023
Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
Read more
Read more
Mar 28, 2023
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics
Read more
Read more
Mar 14, 2023
Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
Read more
Read more
SEE ALL
NEWS
"Psychedelic medications have the potential to revolutionize the way we treat mental health"
James LanthierCEO
James Lanthier
"There is a tremendous opportunity in psychedelics to design safer and more efficacious next-generation medicines"
Joseph AraujoChief Scientific Officer
Joseph Araujo
“The psychedelic medicine space is an IP race and Mindset is in a leadership position”
Malik SlassiSenior VP, Innovation
Malik Slassi
Previous
Next
"Psychedelic medications have the potential to revolutionize the way we treat mental health"
James LanthierCEO
James Lanthier
"There is a tremendous opportunity in psychedelics to design safer and more efficacious next-generation medicines"
Joseph AraujoChief Scientific Officer
Joseph Araujo
“The psychedelic medicine space is an IP race and Mindset is in a leadership position”
Malik SlassiSenior VP, Innovation
Malik Slassi
Meet the team
Meet the team
Get to know us
Let Us Help You
Join the Conversation
Linkedin Youtube Instagram Facebook
Subscribe
Get Updates
Copyright © 2023 Mindset Pharma All rights reserved. | Disclaimer & Privacy Policy
Subscribe for latest news